INDUSTRY NEWS
and therapeutic expertise to drive smarter protocol design and enhance patient safety and compliance.
“According to the International Diabetes Federation (IDF), every six seconds, a person dies from diabetes-related causes and almost half of those deaths are people under the age of 60,” said Margaret Keegan, president of Data Sciences, Safety and Regulatory Services at Quintiles. “With diabetes diagnoses on the rise, the need for innovative and accessible treatments also increases. CGM can provide a variety of in-depth measures from diabetes patients – information that can be used to enhance the way patients are treated for diabetes and why this new offering is so critical.”
Through the offering, continuous glucose measurements will be captured by a wearable sensor and wirelessly sent to a receiver, recording readings throughout the day. In the clinical trial setting, this comprehensive and timely glucose visibility has the potential to improve patient safety, accelerate clinical development and provide a basis for differentiated claims.
“We are excited to bring this new CGM offering to the market as a complement to Quintiles’ technology integration strategy,” said Sam Osman, head of Cardiac Safety Services at Quintiles. “We believe this new technology solution incorporating biosensors and wearables, which can be used across all drug development phases, will improve the way the industry tracks and improves diabetes care for patients worldwide.”
Teewinot Life Sciences Licenses Biosynthetic Technology to AMRI for First Commercially Available CBCA Analytical Standard
Teewinot Life Sciences Corporation and Albany Molecular Research, Inc. (AMRI) have announced that AMRI licensed Teewinot's technology to produce and sell the first commercially available cannabichromene acid (CBCA) analytical standard. The CBCA analytical standard is manufactured using Teewinot's patented biosynthetic processes. Teewinot's proprietary processes involve the expression of cannabinoid biosynthetic genes in microorganisms for efficient production of large quantities of cannabinoids.
"Interest in capturing the therapeutic value of cannabinoids is on the upswing for basic research as well as for pharmaceutical development," said William Marth, president and CEO of AMRI. "As such, companies will need tools that help them ensure their development programs meet the rigorous requirements for drug development. AMRI is continually evaluating and developing technologies for practical production of new, or difficult to synthesize molecules to enhance efficiency and/or quality."
Cannabinoids have therapeutic potential in a number of areas including oncology, pain relief and inflammation, yet until recently, few companies have pursued their study as therapeutic agents. Efforts to advance cannabinoid compounds into therapeutic development will require rigorous testing for quality, safety and
efficacy. This unique analytical standard is one tool that can facilitate research, development, and quality control for pharmaceutical applications of cannabinoids.
"We opted to work with AMRI to scale up the production of our CBCA standard because the company has a global footprint and an exceptional reputation within the field of bioprocess development," said Richard Peet, Teewinot's executive vice president. "Partnering with a leader like AMRI will ensure that the standards available using our biosynthetic platform are consistent and results achieved with them are reproducible."
DHL CARE Award Recognizes Four Major Air Carriers for Excellence in Transporting Temperature-Sensitive Goods and Medications
DHL has recognized the performance of four major air cargo carriers with the first DHL Carrier Award for Reliability and Excellence, DHL CARE Award, which sets a new industry standard for reliability and quality for air-freight transport of temperature-sensitive life sciences products. The first recipients of the new award were: American Airlines, Cathay Pacific, Swiss International Air Lines and United Cargo. The DHL CARE Award was presented at the 16th DHL Global Life Sciences & Healthcare Conference in Miami, Fla. last week, which brought together major pharmaceutical and medical devices manufacturers to discuss industry logistics and supply chain trends.
“It is essential that life sciences products remain in strictly controlled conditions during transportation from pharmaceutical manufacturers to hospitals, medical centers, warehouses, and ultimately to doctors and patients around the world,” said Angelos P. Orfanos, President, Life Sciences & Healthcare Sector, DHL Customer Solutions & Innovation. “The new DHL CARE Award is designed to encourage and recognize air carrier excellence as they put forth great efforts into delivering unrivalled temperature- controlled transportation services for the life sciences sector.”
The four airlines who received the DHL CARE Award achieved the highest ranking out of a pool of 15 carriers who were evaluated in terms of performance, attention to quality and innovative leadership. The ranking included such performance and excellence indicators as shipment temperature consistency, effective communication, process compliance, airport hub assessments and near-real-time data sharing.
David Bang, Global Head of DHL Temperature Management Solutions/CEO LifeConEx at DHL Global Forwarding, pointed out during the award ceremony that as the leading freight forwarder for the Life Sciences and Healthcare sector, DHL is responsible for the safe transportation of pharmaceutical goods and equipment around the world. It is essential for DHL Global Forwarding to establish, maintain, and monitor shipment quality standards at every transportation and storage stage of the end-to-end supply
Pharmaceutical Outsourcing | 44 | July/August 2016
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54